<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) is a <z:hpo ids='HP_0011010'>chronic</z:hpo> relapsing multisystem disease characterized by <z:e sem="disease" ids="C0149745" disease_type="Disease or Syndrome" abbrv="">oral ulceration</z:e>, <z:e sem="disease" ids="C0151281" disease_type="Disease or Syndrome" abbrv="">genital ulceration</z:e> and ocular lesions </plain></SENT>
<SENT sid="1" pm="."><plain>Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate </plain></SENT>
<SENT sid="2" pm="."><plain>We treated a 47-year-old Korean man with BD who had a recurrent <z:mp ids='MP_0000512'>intestinal ulcer</z:mp> with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled <z:hpo ids='HP_0002584'>intestinal bleeding</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option </plain></SENT>
</text></document>